Year 2025 / Volume 117 / Number 11
Letter
Effectiveness of infliximab in common variable immunodeficiency associated with enteropathy

677-678

DOI: 10.17235/reed.2023.10032/2023

Rodrigo Quera, Paulina Núñez Figueroa, Pía Zañartu, Luis Contreras,

Abstract
Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency in adults, with non-infectious gastrointestinal involvement present in up to 50 % of patients, with the small intestine and colon being the most affected areas. Reports have evaluated the effectiveness of biologic therapy in this scenario. Here, we describe the clinical, endoscopic, and histological findings of a patient who presented a satisfactory response to infliximab.
New comment
Comments
No comments for this article
References
1. Hashash JG, Squire J, Francis FF, et al. An expert opinion/approach: Clinical presentations, diagnostic considerations, and therapeutic options for gastrointestinal manifestations of common variable immune deficiency. Am J Gastroenterol 2022;117:1743-1752. doi10.14309/ajg.0000000000002027
2. Ho HE, Cunningham-Rundles C. Non-infectious complications of common variable immunodeficiency: Updated clinical spectrum, sequelae, and insights to pathogenesis. Front Immunol 2020;11:149.doi: 10.3389/fimmu.2020.00149
3. Prieto Elordui J, Arreba Gonzalez P, Ortiz de Zarate Sagastagoitia J, et al. Infliximab as treatment of severe enteropathy in a patient with common variable immunodeficiency and cytomegalovirus infection. Gastroenterol Hepatol 2018;41:163-164. doi: 10.1016/j.gastrohep.2017.03.002
4. Ruiz de Morales JG, Muñoz F, Hernando M. Successful treatment of common variable immunodeficiency-associated Inflammatory Bowel Disease with Ustekinumab. J Crohns Colitis 2017;11:1154-1155. doi: 10.1093/ecco-jcc/jjx024
5. Sifers T, Hirten R, Mehandru S, et al. Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series. Immunol 2020 Mar;212:108362. doi: 10.1016/j.clim.2020.108362.
Related articles

Letter

Cap polyposis refractory to drug treatment, including infliximab

DOI: 10.17235/reed.2024.10297/2024

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Letter to the Editor

Autoimmune hepatitis as a complication of common variable immunodeficiency

DOI: 10.17235/reed.2018.5280/2017

Citation tools
Quera R, Núñez Figueroa P, Zañartu P, Contreras L. Effectiveness of infliximab in common variable immunodeficiency associated with enteropathy. 10032/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1 visits.
This article has been downloaded 0 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 22/10/2023

Accepted: 27/10/2023

Online First: 06/11/2023

Published: 11/11/2025

Article Online First time: 15 days

Article editing time: 751 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2025 y Creative Commons. The Spanish Journal of Gastroenterology